Floatz logo

Recombinant Human Gm-Csf

Melanoma

Hospital Italiano de Buenos AiresEarly Phase 1Dormant
C
34/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
65/ 100

Competitive context

329 Active assets in the Melanoma cohort.

Asset / SponsorPhaseRating
DACARBAZINE
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase 3BB
Cyclophosphamide
Primmune Therapeutics, Inc.
Phase 4BB
Nivolumab
Bristol-Myers Squibb
Phase 4BB
Epirubicin
Primmune Therapeutics, Inc.
Phase 4BB
Pembrolizumab
Biocon Biologics UK PLC
Phase 4BB

View all 50 →

Same molecule, other indications

Recombinant Human Gm-Csf is also rated in:

Lung Cancer MetastaticDormant
CCC
Indicative ·
53 / 100
View asset →
prostate neoplasmDormant
CC
Indicative ·
46 / 100
View asset →
plasma cell myelomaDormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →